文献检索文档翻译深度研究
Suppr Zotero 插件Zotero 插件
邀请有礼套餐&价格历史记录

新学期,新优惠

限时优惠:9月1日-9月22日

30天高级会员仅需29元

1天体验卡首发特惠仅需5.99元

了解详情
不再提醒
插件&应用
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
高级版
套餐订阅购买积分包
AI 工具
文献检索文档翻译深度研究
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2025

聚焦脂质代谢和炎症的动脉粥样硬化基因治疗方法

Gene Therapy Approaches for Atherosclerosis Focusing on Targeting Lipid Metabolism and Inflammation.

作者信息

Bezsonov Evgeny, Chernyi Nikita, Saruhanyan Mane, Shimchenko Dariia, Bondar Nikolai, Gavrilova Darina, Baig Mirza S, Malogolovkin Alexander

机构信息

Laboratory of Molecular Virology, First Moscow State Medical University (Sechenov University), Moscow 119435, Russia.

Department of Biology and General Genetics, First Moscow State Medical University (Sechenov University), Moscow 105043, Russia.

出版信息

Int J Mol Sci. 2025 Jul 19;26(14):6950. doi: 10.3390/ijms26146950.


DOI:10.3390/ijms26146950
PMID:40725196
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC12295045/
Abstract

Atherosclerosis is a complex disease characterized by pathological thickening of the arterial intima. The mechanisms underlying the induction and progression of atherosclerosis are convoluted and remain under active investigation, with key components such as lipid accumulation and local inflammation being identified. Several risk factors (e.g., metabolic disorders, genetic background, diet, infections) have been shown to exacerbate disease progression, but their roles as clinically relevant markers remain to be established. Despite the growing body of evidence on the molecular pathogenesis of atherosclerosis, there is no effective preventive treatment against the development of this disease. In this review, we focus on gene targets for gene therapy as a novel potential approach to cure and prevent atherosclerosis. We critically review recent research demonstrating the therapeutic potential of viral vector-based (adeno-associated virus (AAV) and lentivirus) gene therapy for the treatment of atherosclerosis. We also summarize alternative gene targets and approaches (e.g., non-coding RNA (ncRNA), micro RNA (miRNA), small interfering RNA (siRNA), antisense oligonucleotide (ASO), CRISPR/Cas9) that aim to limit disease progression. We highlight the importance of local inflammation in the pathogenesis of atherosclerosis and propose gene targets with anti-inflammatory activity to inhibit the pathological inflammatory response. In addition, we provide perspectives on the future development of gene therapeutics and their potential applications. We anticipate that recent advances in gene therapy will help to identify new and effective targets to prevent atherosclerosis.

摘要

动脉粥样硬化是一种以动脉内膜病理性增厚为特征的复杂疾病。动脉粥样硬化发生和发展的潜在机制错综复杂,仍在积极研究中,脂质蓄积和局部炎症等关键因素已被确定。已证实多种危险因素(如代谢紊乱、遗传背景、饮食、感染)会加剧疾病进展,但其作为临床相关标志物的作用仍有待确定。尽管关于动脉粥样硬化分子发病机制的证据越来越多,但尚无针对该疾病发展的有效预防性治疗方法。在本综述中,我们聚焦于基因治疗的基因靶点,这是一种治疗和预防动脉粥样硬化的新型潜在方法。我们批判性地回顾了近期研究,这些研究证明了基于病毒载体(腺相关病毒(AAV)和慢病毒)的基因治疗对动脉粥样硬化的治疗潜力。我们还总结了旨在限制疾病进展的其他基因靶点和方法(如非编码RNA(ncRNA)、微小RNA(miRNA)、小干扰RNA(siRNA)、反义寡核苷酸(ASO)、CRISPR/Cas9)。我们强调局部炎症在动脉粥样硬化发病机制中的重要性,并提出具有抗炎活性的基因靶点以抑制病理性炎症反应。此外,我们还展望了基因治疗的未来发展及其潜在应用。我们预计基因治疗的最新进展将有助于确定预防动脉粥样硬化的新的有效靶点。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ed93/12295045/79e4327ccdaa/ijms-26-06950-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ed93/12295045/4cafa2bb9bdf/ijms-26-06950-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ed93/12295045/6846f91e579c/ijms-26-06950-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ed93/12295045/a20db4a401ea/ijms-26-06950-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ed93/12295045/79e4327ccdaa/ijms-26-06950-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ed93/12295045/4cafa2bb9bdf/ijms-26-06950-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ed93/12295045/6846f91e579c/ijms-26-06950-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ed93/12295045/a20db4a401ea/ijms-26-06950-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ed93/12295045/79e4327ccdaa/ijms-26-06950-g004.jpg

相似文献

[1]
Gene Therapy Approaches for Atherosclerosis Focusing on Targeting Lipid Metabolism and Inflammation.

Int J Mol Sci. 2025-7-19

[2]
Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis.

Cochrane Database Syst Rev. 2021-4-19

[3]
Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis.

Cochrane Database Syst Rev. 2020-1-9

[4]
Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis.

Cochrane Database Syst Rev. 2017-12-22

[5]
Systemic treatments for metastatic cutaneous melanoma.

Cochrane Database Syst Rev. 2018-2-6

[6]
The Black Book of Psychotropic Dosing and Monitoring.

Psychopharmacol Bull. 2024-7-8

[7]
Falls prevention interventions for community-dwelling older adults: systematic review and meta-analysis of benefits, harms, and patient values and preferences.

Syst Rev. 2024-11-26

[8]
Psychological interventions for adults who have sexually offended or are at risk of offending.

Cochrane Database Syst Rev. 2012-12-12

[9]
Macrolide antibiotics (including azithromycin) for cystic fibrosis.

Cochrane Database Syst Rev. 2024-2-27

[10]
Factors that influence participation in physical activity for people with bipolar disorder: a synthesis of qualitative evidence.

Cochrane Database Syst Rev. 2024-6-4

本文引用的文献

[1]
Procedural and Antithrombotic Therapy Optimization in Patients with Atrial Fibrillation Undergoing Percutaneous Coronary Intervention: A Narrative Review.

J Cardiovasc Dev Dis. 2025-4-8

[2]
Cost comparison analysis of onasemnogene abeparvovec and nusinersen for treatment of patients with spinal muscular atrophy type 1 in the Netherlands.

Eur J Health Econ. 2025-2-21

[3]
Role of shear stress-induced red blood cell released ATP in atherosclerosis.

Am J Physiol Heart Circ Physiol. 2025-4-1

[4]
The health economics of cell and gene therapies.

Handb Clin Neurol. 2024

[5]
Modeling human atherosclerotic lesions in the test tube: Are we there yet?

Atherosclerosis. 2024-11

[6]
SARS-CoV-2 infection boosts inflammation in atherosclerotic plaques.

Nat Cardiovasc Res. 2023-11

[7]
Cellular metabolism changes in atherosclerosis and the impact of comorbidities.

Front Cell Dev Biol. 2024-8-12

[8]
Aberrant mitochondrial DNA synthesis in macrophages exacerbates inflammation and atherosclerosis.

Nat Commun. 2024-8-26

[9]
Revolutionary breakthrough: FDA approves CASGEVY, the first CRISPR/Cas9 gene therapy for sickle cell disease.

Ann Med Surg (Lond). 2024-5-15

[10]
MicroRNA-19a-3p inhibits endothelial dysfunction in atherosclerosis by targeting JCAD.

BMC Cardiovasc Disord. 2024-7-30

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

推荐工具

医学文档翻译智能文献检索